Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

240.69
+3.591.51%
Post-market: 242.001.31+0.54%19:38 EDT
Volume:1.64M
Turnover:393.46M
Market Cap:32.11B
PE:42.83
High:243.02
Open:235.94
Low:233.33
Close:237.10
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.03
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.72
PE(LYR):103.30

Loading ...

How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny

Simply Wall St.
·
May 29

Alnylam shareholders back executive pay in advisory vote at annual meeting

Reuters
·
May 28

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Insulet (PODD)

TIPRANKS
·
May 27

Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake

Simply Wall St.
·
May 23

J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Alnylam Pharmaceuticals Inc : JP Morgan Resumes Coverage With Overweight Rating; Price Target $420

THOMSON REUTERS
·
May 20

Alnylam Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
May 19

Alnylam publishes 2025 corporate responsibility report

Reuters
·
May 19

Alnylam Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Target Price $380

THOMSON REUTERS
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

Alnylam initiated with a Buy at Citi

TIPRANKS
·
May 19

Alnylam’s New Phase 1 ALN-4915 Trial: Early Safety Data in Focus for ALNY Investors

TIPRANKS
·
May 15

PLTR, KTOS, ALNY: 3 High P/E Stocks with 40%+ Upside Potential in 2026

TIPRANKS
·
May 13

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-05-12

Reuters
·
May 13

Alnylam announces new analyses from HELIOS-B study of vutrisiran

TIPRANKS
·
May 12

Alnylam says HELIOS-B analysis shows vutrisiran benefit across ATTR-CM patient groups

Reuters
·
May 12

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across Attr-Cm Patient Populations, Including Patients With a High Disease Burden

THOMSON REUTERS
·
May 12

Alnylam to webcast investor conference presentations at BofA, Goldman Sachs healthcare events

Reuters
·
May 07

Tenaya Therapeutics Q1 net loss widens, misses analyst expectations

Reuters
·
May 07